Differential Expression and Prognostic Value of Cytoplasmic and Nuclear Cyclin D1 in Prostate Cancer

Table 2

Cytoplastic and nuclear CCND1 expression status in TMA.

Variables	Samples	Percentage	Cytoplasmic CCND1			Nuclear CCND1
			Weak	Strong		Weak	Strong
Tissue type					<0.001			<0.001
Prostate cancer	188	50.00%	103	85		82	106
Adjacent tissue	188	50.00%	53	135		117	71
pT stage					<0.001			0.931
pT2	113	60.11%	50	63		49	64
pT3+pT4	75	39.89%	53	22		33	42
Gleason score					0.028			0.4
≤6	20	10.64%	8	12		11	9
7	89	47.34%	43	46		35	54
≥8	79	42.02%	52	27		36	43
Preoperative PSA level (ng ml-1)					0.142			0.63
<4	3	1.60%	1	2		1	2
4–10	36	19.15%	30	6		19	17
10–20	70	37.23%	37	33		28	42
>20	79	42.02%	50	29		34	45
pN stage					0.177			0.425
p N0	156	82.98%	82	74		66	90
p N1	32	17.02%	21	11		16	16
Surgical margin					0.037			0.945
Positive	82	43.62%	52	30		36	46
Negative	106	56.38%	51	55		46	60
Prostate capsule invasion					0.04			0.682
Positive	68	36.17%	44	24		34	34
Negative	120	63.83%	59	61		51	69
Seminal vesicle invasion					0.294			0.811
Positive	42	22.34%	26	16		19	23
Negative	146	77.66%	77	69		63	83
Nerve invasion					0.285			0.324
Positive	81	43.09%	48	33		32	49
Negative	107	56.91%	55	52		50	57